ASH: Long-term CAR-T data look good for Gilead—but good enough to top its rivals?

11th December 2017 Uncategorised 0

Gilead got a boost over the weekend with some positive longer-term data on closely watched CAR-T drug Yescarta. But whether it’s enough to elevate the drug over its competitors remains to be seen.

More: ASH: Long-term CAR-T data look good for Gilead—but good enough to top its rivals?
Source: fierce